Overview

Our History

Leadership Team

Partner

Portfolio Advisory Board

Peer Reviewed Publications

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Corporate Communications

Hot Job Openings

Investor Relations

Corporate Governance

Financial Report

Announcements and Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock Information (2552.HK)

Financial Report

Company Overview

Pipeline

Team

News

Aug 12, 2026

[NEWS]Hua Medicine Announces First Prescription of Dorzagliatin Dispensed in Hong Kong, China

Hua?Medicine?("the?Company",?HKEX?Stock?Code:?2552)?announced?today?that?dorzagliatin?(trade?name:?MYHOMSIS?,?華領片?),?the?Company's?first-in-class?glucosekinase?activator?(GKA),?has?been?dispensed?its?first?prescription?in?Hong?Kong.

Jul 06, 2026

[NEWS] Hua Medicine Enters Research Collaboration Agreement with GemVCare to Generate Real-World Evidence for Dorzagliatin in Hong Kong

Hua?Medicine?("the?Company",?Hong?Kong?Stock?Exchange?Stock?Code:?2552)?announced?today?that?it?has?entered?a?scientific?research?collaboration?agreement?with?GemVCare?(referred?to?as?GVC),?a?Hong?Kong-based?biotechnology?enterprise.?Leveraging?their?respective?core?strengths,?the?two?parties?will?conduct?joint?clinical?trial?and?real-world?research?using?dorzagliatin?(trade?name:?MYHOMSIS?,?華領片?)?

Jun 30, 2026

[NEWS] Hua Medicine's Dorzagliatin Approved for Type 2 Diabetes Treatment in Macao SAR, China

Hua?Medicine?("the?Company",?Hong?Kong?Stock?Exchange?Stock?Code:?2552)?announced?today?that?its?global?first-in-class?glucokinase?activator?(GKA)?dorzagliatin?(trade?name?in?Macao:?MYHOMSIS?,?華領片?)?has?been?approved?for?marketing?by?the?Pharmaceutical?Administration?Bureau?of?the?Macao?Special?Administrative?Region?for?the?treatment?of?Type?2?diabetes?in?adults.

Calendar

Aug 13, 2026

Mar 16, 2026

Aug 18, 2025

Email

ir@huamedicine.com

Corporate Governance

Contact Us

No.275 Ai Di Sheng Road, Zhangjiang Hi-Tech Park, Pudong, Shanghai 201203

Introduction

News

Calendar

About Us

Overview

Our History

Leadership Team

Portfolio Advisory Board

Partner

Media center

Research & Development

Inovation

Dorzagliatin

mGluR5

Presentations

Peer Reviewed Publications

Media

Company News

Media Releases

Video

Investor Relations

Corporate Governance

Financial Report

Announcements & Circulars

Listing Documents

Investor Presentation

IR Contact

Investor Calendar

Stock information

Careers

Culture

Join Us

Products&Pipeline

Pipeline

HuaTangNing(华堂宁?)

Focus Us

沪公网安备 31011502013809号 Privacy Statement Terms of Use

How we use cookies

Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.

Hot Job Openings

Investor Relations

Financial Report

Company Overview

Pipeline

Team

News

[NEWS]Hua Medicine Announces First Prescription of Dorzagliatin Dispensed in Hong Kong, China

[NEWS] Hua Medicine Enters Research Collaboration Agreement with GemVCare to Generate Real-World Evidence for Dorzagliatin in Hong Kong

[NEWS] Hua Medicine's Dorzagliatin Approved for Type 2 Diabetes Treatment in Macao SAR, China

Calendar

2026 Interim Results Investor Call

2025 Annual Results Investor Call

2025 Interim Results Earnings Call

Email

Corporate Governance

Contact Us